269 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 269 shares of the biopharmaceutical company’s stock, valued at approximately $63,000.

Other institutional investors have also recently made changes to their positions in the company. Allstate Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $894,000. DnB Asset Management AS boosted its holdings in Alnylam Pharmaceuticals by 5.3% in the fourth quarter. DnB Asset Management AS now owns 26,733 shares of the biopharmaceutical company’s stock worth $6,291,000 after acquiring an additional 1,335 shares in the last quarter. Orion Portfolio Solutions LLC boosted its holdings in Alnylam Pharmaceuticals by 5.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 3,744 shares of the biopharmaceutical company’s stock worth $881,000 after acquiring an additional 203 shares in the last quarter. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $577,941,000. Finally, Sava Infond d.o.o. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $407,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 4.3 %

Shares of NASDAQ ALNY opened at $266.83 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $34.71 billion, a PE ratio of -122.96 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business’s fifty day moving average price is $260.16 and its 200-day moving average price is $260.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research report on Monday. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Royal Bank of Canada boosted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, Bank of America increased their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $316.25.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.